15 Stocks That Took a Nosedive in January
Historically, the S&P 500's performance in January sets the pace for the rest of the year.
Crinetics Pharmaceuticals Inc. (CRNX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Driehaus Capital Richard Driehaus | 6,141,014 | $313,990,046 | +5% | 2.59% |
| 2. | EcoR1 Capital Oleg Nodelman | 4,288,120 | $219,251,576 | 8.28% | |
| 3. | Farallon Capital Thomas Steyer | 4,075,098 | $208,359,761 | +251% | 1.05% |
| 4. | Point72 Asset Management Steve Cohen | 2,788,939 | $142,598,462 | +22% | 0.31% |
| 5. | Siren L.L.C. Raymond Debbane | 1,609,652 | $82,301,507 | 3.63% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.06 | 5,000 | Director | 5,000 | 2023-06-08 | Filing | |
| $22.22 | 157,515 | Large Shareholder | 5,321,032 | 2022-04-18 | Filing | |
| $19.80 | 1,200,000 | Large Shareholder | 5,163,517 | 2021-10-25 | Filing | |
| $16.44 | 304,136 | Large Shareholder | 3,963,517 | 2021-04-08 | Filing | |
| $13.10 | 4,000 | Officer, Director | 4,000 | 2020-12-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $39.07 | 5,000 | 31,748 | 2025-02-03 | Filing | ||
| $52.09 | 15,000 | 29,248 | 2025-01-03 | Filing | ||
| $57.57 | 10,000 | 100,000 | 2024-12-02 | Filing | ||
| $56.52 | 501 | 51,653 | 2024-11-22 | Filing | ||
| $54.63 | 14,375 | 28,507 | 2024-10-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,089,391 | $464,740,562 | 0% | |
| 2. | 8,928,086 | $456,493,033 | 0.02% | |
| 3. | 7,515,193 | $384,251,818 | 0% | |
| 4. | 6,950,567 | $355,382,491 | 0.06% | |
| 5. | 2,990,838 | $152,921,547 | 0% |
News See All
Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing.
12 Biotech Stocks with the Biggest Upside Potential
While 2024 was a "challenging" year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q3 2024 Earnings Call Transcript
Operator: Welcome to the Crinetics Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
10 Best Mid-Cap Healthcare Stocks To Buy Now
According to projections by ReportLinker, the market for healthcare services will increase from $7.5 trillion in 2022 to $7.975 trillion in 2023.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q2 2024 Earnings Call Transcript
Operator: Good day everyone, and welcome to the Crinetics Pharmaceuticals Second Quarter 2024 Earnings Conference Call. [Operator Instructions]. Please note this call may be recorded.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q1 2024 Earnings Call Transcript
Operator: Welcome to the Crinetics Pharmaceuticals First Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode.
2024 SOHN Conference Stock Pitches
We were one of the media sponsors of the 2024 Sohn Investment Conference in New York City on April 3rd and we will be sharing our takeaways with our premium subscribers over the next few days.
Insiders Are Dumping These 5 Healthcare Stocks
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) is a clinical stage biopharma company that is working on treatments for endocrine-related diseases.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2023 Earnings Call Transcript
Operator: Welcome to the Crinetics Pharmaceuticals Fourth Quarter and Full-Year 2023 Financial Results Conference Call. At this time all participants are in listen-only mode.
Billionaire Hedge Funds
